TF and chronic kidney disease: Previous studies reported that treatment with intravenous iron such as ferric carboxymaltose (FCM) and iron dextran increased hemoglobin (Hb), serum ferritin, and transferrin saturation (TSAT), and decreased cFGF23 levels in non-CKD patients with IDA.